Long-term efficacy of adeno-associated virus serotypes 8 and 9 in hemophilia a dogs and mice

Human Gene Therapy

Volumn 17, Issue 4, 2006, Pages 427-439

  Sarkar, Rita ^a   Mucci, Melinda ^a   Addya, Sankar ^b   Tetreault, Renee ^a   Bellinger, Dwight A ^c   Nichols, Timothy C ^c   Kazazian Jr , Haig H ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; CYCLOPHOSPHAMIDE; PARVOVIRUS VECTOR; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ADENO ASSOCIATED VIRUS; ARTICLE; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HEAVY CHAIN; HEMOPHILIA A; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; KNOCKOUT MOUSE; LIGHT CHAIN; MALE; MOUSE; NONHUMAN; PORTAL VEIN; SPECIES DIFFERENCE; TRANSGENE; VIRAL GENE THERAPY;

ANIMALS; CYCLOPHOSPHAMIDE; DEPENDOVIRUS; DOGS; FACTOR VIII; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HEMOPHILIA A; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PORTAL VEIN; TIME FACTORS; TRANSGENES;

ADENO-ASSOCIATED VIRUS; ANIMALIA; CANIS FAMILIARIS; PARVOVIRUS;

EID: 33645908797     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2006.17.427     Document Type: Article

References (38)

1. ARRUDA, V.R., FIELDS, P.A., MILNER, R., WAINWRIGHT, L., MIGUEL, M.P.D., DONOVAN, P.J., HERZOG, R.W., NICHOLS, T.C., BIEGEL, J.A., RAZAVI, M., DAKE, M., HUFF, D., FLAKE, A.W., COUTO, L., KAY, M.A., and HIGH, K.A. (2001). Lack of germ line transmission of vector sequence following systematic administration of recombinant AAV2 vectors in males. Mol. Ther. 4, 586-592.
2. BI, L., LAWLER, A.M., ANTONARAKIS, S.E., HIGH, K.A., GEARHART, J.D., and KAZAZIAN, H.H., Jr. (1995). Targeted disruption of the mouse FVIII gene produces a model of hemophilia A. Nat. Genet. 10, 119-121.
3. CHAO, H., MAO, L., BRUCE, A.T., and WALSH, C.E. (2000). Sustained expression of human factor VIII in mice using a parvovirus-based vector. Blood 95, 1594-1599.
4. DAVIDOFF, A.M., NG, C.Y., ZHOU, J., SPENCE, Y., and NATHWANI, A.C. (2003). Sex significantly influences transduction of murine liver by recombinant adeno-associated viral vectors through an androgen-dependent pathway. Blood 102, 480-488.
5. FERRARI, F.K., SAMULSKI, T., SHENK, T., and SAMULSKI, R.J. (1996). Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J. Virol. 70, 3227-3234.
6. GAO, G., QU, G., BURNHAM, M.S., HUANG, J., CHIRMULE, N., JOSHI, B., YU, Q.C., MARSH, J.A., CONCEICAO, C.M., and WILSON, J.M. (2000). Purification of recombinant adeno-associated virus vectors by column chromatography and its performance in vivo. Hum. Gene Ther. 11, 2079-2209.
7. GAO, G., VANDENBERGHE, L.H., ALVIRA, M.R., LU, Y., CALCEDO, R., ZHOU, X., and WILSON, J.M. (2004). Clades of adeno-associated viruses are likely disseminated in human tissues. J. Virol. 78, 6381-6388.
8. GAO, G., VANDENBERGHE, L.H., and WILSON, J.M. (2005). New recombinant serotypes of AAV vectors. Curr. Gene Ther. 5, 285-297.
9. GAO, G.P., QU, G., FAUST, L.Z., ENGDAHL, R.K., XIAO, W., HUGHES, J.V., ZOLTICK, P.W., and WILSON, J.M. (1998). High-liter adeno-associated viral vectors from a Rep/Cap cell line and hybrid shuttle virus. Hum. Gene Ther. 9, 2353-2362.
10. GAO, G.P., ALVIRA, M.R., WANG, L., CALCEDO, R., JOHNSTON, J., and WILSON, J.M. (2002). Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. U.S.A. 99, 11854-11859.
11. GRIMM, D., and KAY, M.A. (2003). From virus to vector revolution: Use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy. Curr. Gene Ther. 3, 281-304.
12. HIGH, K.A. (2004). Clinical gene transfer studies for hemophilia B. Semin. Thromb. Hemost. 30, 257-267.
13. HIGH, K.A., MANNO, C.S., SABATINO, D.E., HUTCHISON, S., DAKE, M., and RAZAVI, M. (2004). Immune responses to AAV and to factor IX in a phase I study of AAV-mediated, liver-directed gene transfer for hemophilia B [abstract]. Mol. Ther. 5, S1002.
14. KAY, M.A., MANNO, C.S., RAGNI, M.V., LARSON, P.J., COUTO, L.B., MCCLELLAND, A., GLADER, B., CHEW, A., TAI, S.J., HERZOG, R.W., ARRUDA, V., JOHNSON, F., SCALLAN, C., SKARSGARD, E., FLAKE, A.W., and HIGH, K.A. (2000). Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat. Genet. 24, 257-261.
15. ΔΔCT method. Methods 25, 402-408.
16. MAH, C, SARKAR, R., ZOLOTUKHIN, I., SCHLEISSING, M., XIAO, X., KAZAZIAN, H.H., and BYRNE, B.J. (2003). Dual vectors expressing murine factor VIII results in sustained correction of hemophilia A mice. Hum. Gene Ther. 14, 143-152.
17. MANNO, C.S., CHEW, A.J., HUTCHISON, S., LARSON, P.J., HERZOG, R.W., ARRUDA, V.R., TAI, S.J., RAGNI, M.V., THOMPSON, A., OZELO, M., COUTO, L.B., LEONARD, D.G.B., JOHNSON, F.A., MCCLELLAND, A., SCALLAN, C., SKARSGARD, E., FLAKE, A.W., KAY, M.A., HIGH, K.A., and GLADER, B. (2003). AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 101, 2963-2972.
18. MANNO, C.S., ARRUDA, V.R., PIERCE, G.F., GLADER, B., RAGNI, M., RASKO, J., OZELO, M.C., HOOTS, K., BLATT, P., KONKLE, B., DAKE, M., KAYE, R., RAZAVI, M., ZAJKO, A., ZEHNDER, J., NAKAI, H., CHEW, A., LEONARD, D., WRIGHT, J.F., LESSARD, R., SOMMER, J., TIGGES, M., SABATTNO, D., LUK, A., JIANG, H., MINGOZZI, F., COUTO, L., ERTL, H.C., HIGH, K.A., and KAY, M.A. (2006). Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. 12, 342-347.
19. MOUNT, J.D., HERZOG, R.W., TILLSON, D.M., GOODMAN, S.A., ROBINSON, N., MCCLELAND, M.L., BELLINGER, D., NICHOLS, T.C., ARRUDA, V.R., LOTHROP, C.D., Jr., and HIGH, K.A. (2003). Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood 101, 3338-3339.
20. NAKAI, H., THOMAS, C.E., STORM, T.A., FUESS, S., POWELL, S., WRIGHT, J.F., and KAY, M.A. (2002). A limited number of transducible hepatocytes restricts a wide-range linear vector dose response in rAAV-mediated liver transduction. J. Virol. 76, 11343-11349.
21. NAKAI, H., FUESS, S., STORM, T.A., MURAMATSU, S., NARA, Y., and KAY, M.A. (2005). Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice. J. Virol. 79, 214-224.
22. NATHWANI, A.C., DAVIDOFF, A.M., HANAWA, H., HU, Y., HOFFER, F.A., NIKANOROV, A., SLAUGHTER, C., NG, C.Y.C., ZHOU, J., LOZIER, J.N., MANDRELL, T.D., VANIN, E.F., and, NIENHUIS, A.W. (2002). Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques. Blood 100, 1662-1669.
23. RABINOWITZ, J.E., ROLLING, F., LI, C., CONRATH, H., XIAO, W., XIAO, X., and SAMULSKI, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791-801.
24. RUSSELL, K.E., OLSEN, E.H., RAYMER, R.A., MERRICKS, E.P., BELLINGER, D.A., READ, M.S., RUP, B.J., KEITH, J.C., Jr., MCCARTHY, K.P., SCHAUE, R.G., and NICHOLS, T.C. (2003). Reduced bleeding events with subcutaneous administration of recombinant factor IX in immune tolerant hemophilia B dogs. Blood 102, 4393-4398.
25. SAMBROOK, J., MANIATIS, T., and FRITSCH, E.F. (1998). Molecular Cloning: A Laboratory Manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
26. SANLIOGLU, S., BENSON, P.K., YANG, J., ATKINSON, E.M., REYNOLDS, T., and ENGELHARDT, J.F. (2000). Endocytosis and nuclear trafficking of adeno-associated virus type 2 are controlled by rac I and phosphatidylinositol-3 kinase activation. J. Virol. 74, 9184-9196.
27. SARKAR, R., XIAO, W., and KAZAZIAN, H.H. (2003). A single adeno-associated virus (AAV)-murine factor VIII vector partially corrects the hemophilia A phenotype. J. Thromb. Hemost. 1, 218-224.
28. SARKAR, R., TETREAULT, R., GAO, G.P., WANG, L., BELL, P., CHANDLER, R., WILSON, J.M., and KAZAZIAN, H.H., Jr. (2004). Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype. Blood 103, 1253-1260.
29. SCALLAN, C.D., LILLICRAP, D., JIANG, H., QIAN, X., PATARROYO-WHITE, S.L., PARKER, A.E., LIU, T., VARGAS, J., NAGGY, D., POWELL, S.K., WRIGHT, J.F., TURNER, P.V., TINLIN, S.J., WEBSTER, S.E., MCCLELLAND, A., and COUTO, L.B. (2003a). Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector. Blood 102, 2031-2037.
30. SCALLAN, C.D., LUI, T., PARKER, A.E., PATARROYO-WHITE, S.L., CHEN, H., JIANG, H., VARGAS, J., NAGY, D., POWELL, S.K., WRIGHT, J.F., SARKAR, R., KAZAZIAN, H.H., MCCLELLAND, A., and COUTO, L.B. (2003b). Phenotypic correction of a mouse model of hemophilia A using AAV2 vectors encoding the heavy and light chains of FVIII. Blood 102, 3919-3926.
31. SEISENBERGER, G., RIED, M.U., ENDRESS, T., BUNING, H., HALLEK, M., and BRAUCHLE, C. (2001). Real-time single molecule imaging of the infection pathway of an adeno-associated virus. Science 294, 1929-1932.
32. SNYDER, R.O., XIAO, X., and SAMULSKI, R.J. (1996). Production of recombinant adeno-associated viral vectors. In: Dracopoli, N., Haines, J., Krof, B., Moir, D., Morton, C., Seidman, C., Seidman, J., and Smith, D., eds. Current Protocols in Human Genetics, Vol. 1, pp. 1-24. John Wiley & Sons, New York.
33. THOMAS, C.E., STORM, T.A., HUANG, Z., and KAY, M.A. (2004). Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. J. Virol. 78, 3110-3122.
34. WANG, L., NICHOLS, T.C., READ, M.S., BELLINGER, D.A., and VERMA, I.M. (2000). Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver. Mol. Ther. 1, 154-158.
35. WANG, L., CALCEDO, R., NICHOLS, T.C., BELLINGER, D.A., DILLOW, A., VERMA, I.M., and WILSON, J.M. (2005). Sustained correction of disease in naïve and AAV2-pretreated hemophilia B dogs: AAV2/8 mediated, liver-directed gene therapy. Blood 105, 3079-3086.
36. XIAO, X., LI, J., and SAMULSKI, R.J. (1998). Production of recombinant adeno-associated viral vectors in the absence of helper adenovirus. J. Virol. 72, 2224-2232.
37. XU, L., NICHOLS, T.C., SARKAR, R., MCCORQUODALE, S., BELLINGER, D.A., and PONDER, K.P. (2005). Absence of a desmopressin response after therapeutic expression of factor VIII in hemophilia A dogs with liver directed neonatal gene therapy. Proc. Natl. Acad. Sci. U.S.A. 102, 6080-6085.
38. ZHONG, L., LI, W., YANG, Z., CHEN, L., LI, Y., QING, K., WEIGEL-KELLEY, K.A., YODER, M.C., SHOU, W., and SRIVASTAVA, A. (2004). Improved transduction of primary murine hepatocytes by recombinant adeno-associated virus 2 vectors in vivo. Gene Ther. 11, 1165-1169.